Impact of Hormonal Therapy on Prostate Cancer Recurrence After Radical Prostatectomy

Prostate cancer is the most common cancer in men and radical prostatectomy is the most frequent treatment for this disease. Unfortunately, approximately 40% of patients will develop recurrence after surgery, requiring additional salvage radiation. Salvage radiation after recurrence is successful in less than half of these men and most of those die from their disease. Measures to prevent recurrence are an important research priority for prostate cancer patients and their families. Hormonal therapy (androgen deprivation therapy; ADT) is routinely used to treat patients with metastases, but few c

Trial Details

NCT ID

NCT05169112

Phase

PHASE3

Sponsor

Ottawa Hospital Research Institute

Status

RECRUITING

Cancer Type

Prostate Cancer

Interventions

Lupron Depot

Locations (sample)

Halifax, Nova Scotia, Canada|44.64269,-63.57688
Ottawa, Ontario, Canada|45.41117,-75.69812
Montreal, Quebec, Canada|45.50884,-73.58781

Key Eligibility Criteria

undetectable PSA (\<0.02 ng/ml) within 16 weeks post-operative;
≥25% predicted risk of PSA recurrence within 5 years of surgery (based on the Kattan nomogram)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Prostate Cancer Trials on Trialify →